Sandbox/ammth
< Sandbox
Dosing Frequency and the Level Of Evidence[1]
|
- The level of evidence of the dosage frequency came from the systematic review showed that equivalent efficacy of daily intensive-phase dosing followed by two times weekly continuation phase, however twice weekly dosing is not recommended on operational grounds. Also showed that the daily (rather than three times weekly) intensive-phase dosing may also help to prevent acquired drug resistance in TB patients starting treatment with isoniazid resistance. The systematic review found that patients with isoniazid resistance treated with a three times weekly intensive phase had significantly higher risks of failure and acquired drug resistance than those treated with daily dosing during the intensive phase.[2]
Standard regimens for new TB patients (with presumed, or known, to have drug-susceptible TB)
Preferred regimen | Alternative regimen | Alternative regimen |
---|---|---|
Initial phase Daily INH,RIF,PZA and EMB for 56 doses(8 weeks) |
Initial phase Daily INH, RIF, PZA, and EMB* for 14 doses (2 weeks), then twice weekly for 12 doses (6 weeks) |
Initial phase Thrice-weekly INH, RIF, PZA, and EMB* for 24 doses (8 weeks) |
Continuation Phase Daily INH and RIF for 126 doses (18 weeks) or Twice-weekly INH and RIF for 36 doses (18 weeks) |
Continuation Phase Twice-weekly INH and RIF for 36 doses (18 weeks) |
Continuation Phase Thrice-weekly INH and RIF for 54 doses (18 weeks) |
Isoniazid (INH)
rifampin (RIF)
ethambutol (EMB)
pyrazinamide (PZA)
- DOT; Direct Observed Therapy
- † if patient is getting DOT and not living with HIV infected patient or HIV prevalent setting
- ↑ Empty citation (help)
- ↑ "http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf" (PDF). External link in
|title=
(help)